Citations

Clear

3 citation(s) found for "Singh, Aman".

Burden of Emergency Department Visits and Their Outcomes Among Patients With Rheumatoid Arthritis: Insights From the Nationwide Emergency Department Sample
Bharadiya, Vishwesh , Berry, Parul , Singh, Aman Dev , Feterman, Dominique, Bays, Alison , Stovall, Rachael , Dhital, Rashmi , Bharadiya, Vishwesh , Bays, Alison , Stovall, Rachael , Dhital, Rashmi , Singh, Namrata , Hughes, Grant C.

Mayo Clinic

ACR Open Rheumatology | May 6, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1002/acr2.70043 | PMID 40325875 Get It

ObjectivePatients with rheumatoid arthritis (RA) frequently visit emergency departments (EDs), but their clinical characteristics and admission factors are poorly understood. Our study investigates the epidemiology and outcomes of ED visits among patients with RA using the Nationwide Emergency Department Sample (NEDS).MethodsThis cross‐sectional study used the 2019 NEDS data to identify RA‐related ED visits using International Classification of Disease, Tenth Revision codes M05.X or M06.X. RA‐related ED visits were defined as encounters in which RA was recorded in any diagnostic position. Demographics, clinical features, and comorbidities were compared between RA and non‐RA ED visits. Racial variations were assessed, and multivariable logistic regression identified factors associated with inpatient admission.ResultsWe identified 905,811 (0.8%) ED visits for adults aged ≥18 years with RA. Compared to non‐RA visits, RA ED visits had a higher proportion of patients aged ≥65 years, women, White patients, and Medicare‐insured individuals with a greater comorbidity burden. Admission rates were 46% for RA visits versus 16% for non‐RA visits. Black and Hispanic patients with RA were younger than White patients and more likely to belong to the lowest income quartile. Older age, male sex, and comorbidities were associated with higher admission odds, whereas Black race, lowest income quartile, and Medicaid coverage correlated with lower odds of admission. Septicemia was the most common primary ED diagnosis in patients with RA.ConclusionPatients with RA visiting the ED were older, had a higher comorbidity burden, and were three times more likely to be admitted than patients without RA. Black patients and those in the lowest income quartile had lower odds of admission, highlighting potential disparities and the need for targeted interventions to improve health equity.
Traumatic Vertebral Artery Injury After Subaxial Cervical Spine Injuries: Incidence, Risk Factors, and Long-Term Outcomes: A Population-Based Cohort Study
El-Hajj, Victor Gabriel , Habashy, Karl J. , Cewe, Paulina , Atallah, Elias , Singh, Aman , Fletcher‐Sandersjöö, Alexander , Bydon, Mohamad , Fagerlund, Michael, Jabbour, Pascal , Elmi‐Terander, Adrian , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel , Jabbour, Pascal , Gerdhem, Paul , Edström, Erik

Mayo Clinic

Neurosurgery | January 14, 2025 | Volume: 96 | Issue: 4 | Pages: 881-891

10.1227/neu.0000000000003173 | PMID 39808539 Get It

BACKGROUND AND OBJECTIVES: Vertebral artery injury (VAI) because of traumatic subaxial cervical spine injury is a rare but potentially devastating condition as it could lead to stroke. The aim of this study was to examine the incidence, risk factors, outcomes, and radiographic predictors of VAI in patients surgically treated for subaxial cervical spine injuries at a tertiary care trauma center. METHODS: This is a retrospective population-based cohort study, including all patients surgically treated for traumatic subaxial cervical spine injuries at the study center between 2006 and 2018. Primary outcomes included mortality and morbidity after the injury. Propensity score matching, survival, univariable, and multivariable analyses were used to study the outcomes of interest. RESULTS: Traumatic VAI primarily occurred after high-energy traumas such as motor vehicle accidents and falls from heights. The median age was 64.4 years (47.4-69.1), and 69% were male. In the cohort of patients with subaxial cervical injury, 54% had a spinal cord injury (SCI). In the subgroup with VAI, the frequency of SCI was 66% and a concomitant SCI and VAI were associated with a more severe American Spinal Cord Injury Association Impairment Scale grade ( P = .015). However, after accounting for age, sex, and associated injuries, VAI did not affect postoperative complications, short- or long-term outcomes, or mortality rates. Facet joint dislocation was a unique radiographic predictor of VAI (odds ratio 3.8 [CI 1.42-10.7], P = .009). CONCLUSION: The findings suggest that clinical outcomes of patients with traumatic cervical spine injuries were not negatively affected by the presence of a VAI. Several radiographic factors were associated with VAI; however, only facet joint dislocation remained as an independent predictor of this injury.
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio, Michael , Kennedy, Kevin , Putman, Michael , Sirotich, Emily , Sattui, Sebastian E. , Foster, Gary , Harrison, Carly , Larché, Maggie , Levine, Mitchell , Moni, Tarin T , Thabane, Lehana , Bhana, Suleman , Costello, Wendy, Grainger, Rebecca , Machado, Pedro , Sufka, Paul , Wallace, Zachary S. , Gore‐Massy, Monique , Kodhek, More A, Lalonde, Nadine, Tomasella, Laura-Ann, Wallace, John, Akpabio, Akpabio , Alpizar-Rodriguez, D. , Berenbaum, Françis , Buliņa, Inita , Chock, Eugenia Yupei , Duff, Eimear , Hsieh, Evelyn , Kibbi, Lina El, Liew, David , Lo, Chieh , Nudel, Michal, Singh, Aman Dev , Hausmann, Jonathan S. , Sparks, Jeffrey A. , Putman, Michael S , Sirotich, Emily , Sattui, Sebastian E , Machado, Pedro M , Robinson, Philip C , Akpabio, Akpabio , Alpízar-Rodríguez, Deshiré , Berenbaum, Francis , Chock, Eugenia Yupei , Liew, David Fl , Singh, Jasvinder A , Ugarte-Gil, Manuel F , Hausmann, Jonathan S , Simard, Julia F , Sparks, Jeffrey A , Grainger, Rebecca , Hsieh, Evelyn , Thabane, Lehana , Kennedy, Kevin , Liew, Jean W. , Robinson, Philip C. , Yazdany, Jinoos , Howard, Richard A, Wallace, John, Beesley, Richard P. , Conway, Richard , Duarte‐García, Alí , Gheita, Tamer A. , Graef, Elizabeth R. , Singh, Jasvinder A. , Singh, Namrata , Ugarte‐Gil, Manuel F.

Mayo Clinic

RMD Open | September 14, 2022 | Volume: 8 | Issue: 2 | Pages: e002587

10.1136/rmdopen-2022-002587 | PMID 36104117 Get It

Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.